Taking the Pain out of Multiple Sclerosis
Innate Immunotherapeutics Limited
(ASX:IIL) is a clinical stage medical biotechnology company that has designed and developed a proprietary drug – MIS416 - that targets the human innate immune system using a unique immunomodulatory microparticle technology.
This bacteria-derived biologic is currently being trialled as a treatment for Secondary Progressive Multiple Sclerosis (SPMS). MIS416 has also been found to have beneficial application in the treatment of certain cancers, infections and other diseases.
For further information please download PDF attached:
